FDA authorises combination flu-Covid test for home use to help consumers

The Lucira Cpvid-19 & Flu Home test, which can be purchased without a prescription, uses self-collected nasal swab samples and delivers results in about 30 minutes, the agency said

coronavirus
Photo: Bloomberg
AP Washington
2 min read Last Updated : Feb 25 2023 | 11:17 AM IST

Don't want to miss the best from Business Standard?

The Food and Drug Administration on Friday approved the first combination test for flu and C OVID-19 that can be used at home, giving consumers an easy way to determine if a runny nose is caused by either disease.

The Lucira COVID-19 & Flu Home test, which can be purchased without a prescription, uses self-collected nasal swab samples and delivers results in about 30 minutes, the agency said.

While at-home COVID tests are readily available, this is the first home test for influenza A and B, commonly known as the flu. The test was granted an emergency use authorization, which facilitates the availability of medical countermeasures during public health emergencies.

Jeff Shuren, director of the FDA's Center for Devices and Radiological Health, called the authorization a major milestone in bringing greater consumer access to diagnostic tests that can be performed entirely at home.

The agency said the test is for individuals with signs and symptoms consistent with a respiratory tract infection" and said it can be used on children as young as 2, with adults collecting the samples.

It recommends that tests be reported to healthcare providers and cautions that there is a risk of false positive and negative results. Individuals who test negative and continue to experience symptoms of fever, cough and-or shortness of breath may still have a respiratory infection and should seek follow-up care with their healthcare provider, the agency said.

Citing the impact of COVID and RSV, another respiratory infection, the FDA said it recognizes the benefits that home testing can provide and would work to increase the number of tests available.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :CoronavirusFDAFlu

First Published: Feb 25 2023 | 11:17 AM IST

Next Story